On November 22, 2017 Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ("Prima", the "Company") reported the grant of patent number 2604275 entitled "Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response" by the European Patent Office (Press release, Prima Biomed, NOV 22, 2017, View Source [SID1234522226]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This European patent was filed as a divisional application and follows the grant of the European parent patent, which was issued in August 2013.

The claims of this new patent are geared toward the use of Prima’s lead candidate IMP321 in combination with a chemotherapeutic agent for the treatment of cancer. According to the claims, IMP321 elicits a monocyte-mediated immune response and is administered before, with, or subsequent to administration of the chemotherapeutic agent. Importantly, these granted claims support the application of IMP321 in Prima’s AIPAC clinical trial in metastatic breast cancer in Europe.
The patent expiry date is 3 October 2028.